NCT02124746View on ClinicalTrials.gov

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 6, 2018

Study Completion Date

December 6, 2018

Conditions
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPolycythemia VeraEssential Thrombocythemia
Interventions
DRUG

Momelotinib

Momelotinib tablets administered orally once daily

Trial Locations (22)

Unknown

Scottsdale

Orange

Stanford

Whittier

Jacksonville

Baltimore

Boston

Ann Arbor

Rochester

St Louis

New York

The Bronx

Cleveland

Houston

Salt Lake City

Frankston

Parkville

Toronto

Montreal

La Tronche

Paris

Minden

All Listed Sponsors
lead

Sierra Oncology LLC - a GSK company

INDUSTRY

NCT02124746 - Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | Biotech Hunter | Biotech Hunter